



Dr Mark Page

Publications

1. Page M and Rowley AF (1982). A morphological study of pharyngeal lymphoid accumulations in larval lampreys. *Dev Comp Immunol. Suppl 2* : 35-40.
2. Page M and Rowley AF (1983). A cytochemical, light and electron microscopical study of the leucocytes of the adult river lamprey, *Lampetra fluviatilis* (L Gray). *J Fish Biol* 22 : 503-517.
3. Page M and Rowley AF (1984). The reticulo-endothelial system of the adult river lamprey, *Lampetra fluviatilis* (L) : The fate of intravascularly injected colloidal carbon. *J Fish Dis* 7 : 339-353.
4. Rowley AF and Page M (1985). Ultrastructural, cytochemical and functional studies on the eosinophili granulocytes of larval lampreys. *Cell Tiss Res* 240 : 705-709.
5. Rowley AF and Page M (1985). Lamprey melano-macrophages : Structure and function. In: *Fish Immunology* (eds. MJ Manning and MF Tatner), pp 273-284. London Academic Press.
6. Rowley AF, Mainwaring G, Hunt TC and Page M (1988). Fish. In: *Vertebrate Blood Cells* (eds. AF Rowley and NA Ratcliffe). Cambridge: Cambridge University Press.
7. Page M, Hogg J and Ashhurst DE (1986). The effects of mechanical stability on the macromolecules of the connective tissue matrices produced during fracture healing. I. The collagens. *Histochem J* 18 :251-265.
8. Page M and Ashhurst DE (1986). The distribution of types I, II, III and V collagens in healing fractures of the rabbit tibia. In: *Cell Mediated Calcification and Matrix Vesicles* (ed. YS Ali), pp 161-166. Amsterdam Elsevier.
9. Page M and Ashhurst DE (1987). The effects of mechanical stability on the macromolecules of the connective tissue matrices produced during fracture healing. II. The glycosaminoglycans. *Histochem J* 19 : 39-61.
10. Ashhurst DE and Page M (1987). Collagens and glycoaminoglycans associated with fracture healing. In : *Current Advances in Skeletogenesis* (eds. S Hurwitz and J Sela), vol 3, p132. Jerusalem : Heiliger Publishing House.
11. Page M (1988). Changing patterns of cytokeratin and vimentin in the early chick embryo. *Development* 105 : 97-107.
12. Loveless W, Bellairs R, Thorpe SJ, Page M and Feizi T (1990). Developmental patterning of the carbohydrate antigen FC10.2 during early embryogenesis in the chick. *Development* 108 : 97-106.
13. Almond N, Page M, Mills K, Jenkins A, Ling C, Thorpe R and Kitchen P (1990). The production and purification of PCR derived recombinant simian immunodeficiency virus p27 gag protein : Its use in detecting serological and T cell responses in macaques. *J Virol Meth* 28 : 321-326.
14. Kitchen PA, Cranage MP, Almond N, Barnard A, Baskerville A, Corcoran T, Fromholz C, Greenaway P, Grief C, Jenkins A, Kent K, Ling C, Mahon B, Mills K, Page M, Silvera P, Szotyori Z, Taffs F and Stott EJ (1990). Titration of SIVmac251 (32H isolate) in cynomolgus macaques for use as a challenge in vaccination studies. In: *Animal models in AIDS* (eds. H Schellekens and MC Horzine), pp 115-129. Amsterdam : Elsevier Science Publishers.
15. Page M and Thorpe R (1990). Controlling for false positive antisera in human immunodeficiency virus immunoblotting. *J Infect Dis* 162 : 178.
16. Stott EJ, Chan WL, Mills KHG, Page M, Taffs F, Cranage M, Greenaway P and Kitchen P (1991) . Preliminary Report : Protection of cynomolgus macaques against simian immunodeficiency virus by a whole fixed infected cell vaccine. *Lancet* 336 : 1536-1541.



17. Page M, Patel V, Dilger P, Ling C and Thorpe R (1991). Antisera raised against recombinant soluble CD4's can have reactivity to recombinant HIV-1 envelope glycoproteins. *AIDS* 5 : 321-324.
18. Page M, Mills KHG, Schild GC, Ling C, Patel V, McKnight A, Barnard AL, Dilger P and Thorpe R (1991). Studies on the immunogenicity of CHO cell-derived recombinant gp120 (HIV-1_{III}) envelope glycoproteins. *Vaccine* 9 : 47-52.
19. Stott EJ, Kitchen PA, Page M, Flanagan B, Taffs LF, Chan WL, Mills KHG, Silvera P and Rodger A (1991). Anti-cell antibody in macaques. *Nature* 353 : 393.
20. D'Souza P, Durda P, Hanson CV, Milman G and Collaborating Investigators (1991). Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays : An international collaboration. *AIDS* 5 : 1061-1070.
21. Mills KHG, Barnard AL, Williams M, Page et al (1991). Vaccine induced CD4+ T cells against the simian immunodeficiency virus gag protein : Epitope specificity and relevance to protective immunity. *J Immunol* 147 : 3560-3567.
22. Stott J, Cranage M, Kitchen P, Farrar G, Taffs F, Ashworth E, Page M, Chan L, Baskerville A, Greenaway P and Mills K (1991). Vaccination against simian immunodeficiency virus infection of macaques. In : *Retroviruses of human AIDS and related animal diseases. Sixieme colloque des cent gardes 1991* (eds. M Girard and L Valette), pp 261-265, Pasteur Merieux.
23. Thorpe R, Brasher M, Tarelli E, Dilger P and Page M (1992). Laboratory evaluation of IVIG preparations. In : *Clinical Applications of Intravenous Immunoglobulin Therapy* (ed. Peng Lee Yap), pp 253-262. Churchill Livingstone.
24. Page M, Vella C, Corcoran T, Dilger P, Ling C, Heath A and Thorpe R (1992). Restriction of serum antibody reactivity to the V3 neutralising domain of HIV gp120 with progression to AIDS. *AIDS* 6 : 441-446.
25. Cranage M, Stott J, Mills K, Ashworth T, Taffs F, Farrar G, Chan WL, Dennis M, Putkonen P, Biberfeld G, Murphey-Corb M, Baskerville A, Page M, Kitchen P and Greenaway P (1992). Vaccine studies with the 32H reisolate of SIVmac251 : An overview. *AIDS Res and Hum Retro* 8 : 1469-1481.
26. Mills KHG, Page M, Chan WL, Kitchen P, Stott EJ, Taffs F, Jones W et al (1992). Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with KB28 derived recombinant env and gag proteins. *J Med Primatol* 21 : 50-58.
27. D'Souza MP, Kent KA, Thiriart C, Collignon C, Milman G and Collaborating Investigators (1993). International Collaboration comparing neutralization and binding assays for monoclonal antibodies to simian immunodeficiency virus. *AIDS Res and Hum Retro* 5 : 415-422.
28. McKeating JA, Shotten C, Cordell J, Graham S, Balfe P, Sullivan N, Charles M, Page M, Bolmstedt A, Olofsson S, Kayman SC, Wu Z, Pinter A, Dean C, Sodroski J and Weiss RA (1993). Characterisation of neutralizing monoclonal antibodies to linear and conformation dependent epitopes within the first and second variable domains of human and immunodeficiency virus Type 1 gp120. *J Virol* 67 : 4932-4944.
29. Mills KHG, Jones WC, Mahon BP, Katrak K, Taffs F, Stott EJ and Page M (1993). Cellular and humoral responses to poliovirus and tetanus following primary immunization of SIV infected macaques. In : *Animal Models of HIV and other Retroviral Infections* (eds. P Racz, NL Letvin and JC Gluckman), pp 75-85. Basel : Karger.
30. Kitchen P, Mills K, Page M, Taffs F, Chan WL, Cranage M, Farrar G, Greenaway P and Stott EJ (1993). Vaccination of macaques against SIV infection and the significance of host (C8166) cells components. In: *Vaccines '93*. New York : CSHL, Cold Spring Harbor.
31. Stott EJ, Almond N, Kent KA, Chan WL, Cranage MP, Kitchen PA, Mills KHG, Page M and Rud E (1993). Animal models in the development of AIDS vaccines. In : *Retroviruses of Human AIDS and related Animal diseases. Huitieme Colloques des Cent Gardes 1993* (eds. M Girard and L Valette), pp 131-137. Pasteur Merieux.



32. Mills KHG, Page M, Kitchen P, Chan L, Jones W, Silvera P, Corcoran T, Flanagan B, Ling C, Thiriart C et al (1993). Immunisation of macaques with SIV env recombinants : Specificity of T cell and antibody responses and evaluation of protective efficacy. *J Med Primatol* 22 : 103-109.
33. Page M (1994). Viral Safety. In : *Immunochemistry Labfax* (eds. R Thorpe and M Kerr). Bios Scientific Publishers.
34. Brokstad KA, Page M, Nyland H and Haaheim LR (1994). Auto antibodies to myeline basic protein are not present in the serum and cerebrospinal fluid of multiple sclerosis patients. *Acta Neurol. Scand* 89 : 407-411.
35. Brokstad KA, Kalland KH, Page M, Nyland H and Haaheim L (1994). Serum antibodies in MS patients do not recognize HTLV-I, HIV-1, HIV-2 and SIV. *Acta Path Microbiol Immunol Scand* 102 : 514-520.
36. D'Souza MP, Geyer SJ, Hanson CV, Hendry RM, Milman G and Collaborating Investigators (1994). Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays : An international collaboration. *AIDS* 8 : 169-181.
37. Kent KA, Kitchen P, Mills KHG, Page M, Taffs F, Corcoran T, Silvera P, Flanagan B, Powell C, Rose J, Lindin C, Aubertin A-M and Stott EJ (1994). Passive immunization of cynomolgus macaques with immune sera or a pool of neutralizing monoclonal antibodies failed to protect against challenge with SIVmac251. *AIDS Res and Hum Retro* 10 : 189-194.
38. Page M, Baines M and Thorpe R (1994). Preparation of purified immunoglobulin G (IgG). In : *Methods in Molecular Biology. Vol 32 : Basic Protein and Protocols* (ed. J Walker), pp 407-432, New Jersey : Humana Press.
39. Page M, Ling C, Dilger P, Bentley M, Forsey T, Longstaff C and Thorpe R (1995). Fragmentation of therapeutic human immunoglobulin preparations. *Vox. Sang* 69 : 183-194.
40. Kotitschke R, Lange H and Page M (1995). IgG subclass distribution in intravenous immunoglobulin products : Determination of reproducibility of a method of IgG subclass determination. Ring Study of the "Plasma Blood Components" Section of the German Society of Transfusion Medicine and Immunohaematology. *Infusionsther Transfusionsmed* 22 : 360-363.
41. Page M and Thorpe R (1996). Purification of IgG by precipitation with sodium sulfate or ammonium sulfate. In : *The Protein Protocols Handbook*. Ed. Walker JM. Humana Press Inc, NJ, pp 723.
42. Page M and Thorpe R (1996). Purification of IgG using DEAE-Sepharose chromatography. In: *The Protein Protocols Handbook*. Ed Walker JM. Humana Press Inc, NJ pp725.
43. Page M and Thorpe R (1996). Purification of IgG using Ion-exchange HPLC/FPLC. In: *The Protein Protocols Handbook*. Ed. Walker JM. Humana Press Inc, NJ pp727.
44. Page M and Thorpe R (1996). Purification of IgG by precipitation with polyethylene glycol (PEG). In: *The Protein Protocols Handbook*. Ed. Walker JM. Humana Press Inc, NJ pp731.
45. Page M and Thorpe R (1996). Purification of IgG using protein A or protein G. In: *The Protein Protocols Handbook*. Ed. Walker JM. Humana Press Inc, NJ pp733.
46. Page M and Thorpe R (1996). Purification of IgG using gel-filtration chromatography. In: *Protein Protocols Handbook*. Ed. Walker JM. Humana Press Inc, NJ pp735.
47. Page M and Thorpe R (1996). Purification of IgG using affinity chromatography on antigen-ligand columns. In: *The Protein Protocols Handbook*. Ed. Walker JM. Humana Press Inc, NJ pp739.
48. Page M and Thorpe R (1996). Purification of IgG using thiophilic chromatography. In: *The Protein Protocols Handbook*. Ed. Walker M. Humana Press Inc, NJ pp743.
49. Page M and Thorpe R (1996). Analysis of IgG fractions by electrophoresis. In : *The Protein Protocols Handbook*. Ed. Walker JM. Humana Press Inc, NJ pp745.
50. Ferguson M, Minor PD, Garrett AJ, Page M, Thorpe R and Barrowcliffe T (1996). Testing plasma pools for markers of viral contamination : The UK Experience. *Vox Sang* 71 : 21-26.
51. Page M and Thorpe R (1998). Purification of monoclonal antibodies. In: *Methods in Molecular Biology : Immunochemical Protocols*. Ed. Pound JD. Humana Press, Totowa, NJ pp 95-111.



52. Page M and Thorpe R (1998). IgG Purification. In : Methods in Molecular Biology : Immunochemical Protocols. Ed. Pound JD. Humana Press, Totowa, NJ pp 113-119.
53. Jones CD, Page M, Bacon A, Cahill E, Bentley M and Chatfield SN (1998). Characterisation of the T and B cell immune response to a new recombinant pre-S1, pre-S2 and SHB's antigen containing hepatitis B vaccine (Hepagene™) : Evidence for superior anti-SHB's antibody induction in responder mice. *J Viral Hepatitis* 5 : 5-8.
54. Jones CD, Page M, Bacon A, Cahill A, Bentley M and Chatfield SN (1999). T cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHB's antigen-containing hepatitis B vaccine : Demonstration of superior anti-SHB's antibody induction in responder mice. *Vaccine* 17 : 2528-2537.
55. Page M, Jones CC and Bailey CC (2001). Review : A novel recombinant triple antigen hepatitis B vaccine (Hepacare). *Intervirology* 44 : 88-97.
56. June M-C, Gruner N, Zachoval W, Schraut W, Gerlach T, Diepolder H, Schirren A, Page M, Bailey J, Birtles E, Whitehead E, Trojan J, Zeuzem S and Pape GR (2002). Immunological monitoring during therapeutic vaccination as a pre-requisite for the design of new effective therapies : Induction of a vaccine specific CD4+ T cell proliferative response in chronic hepatitis B carriers. *Vaccine* 20 : 3598.
57. Page, M, Ojugo, A, Imami, N, Hardy, G, Gotch, F and Almond, N (2007). Specificity of anti-human leukocyte antigen antibody responses after immunization with Remune, an inactivated HIV-1 vaccine. *AIDS* 21: 375-7.
58. Das, AT, Klaver B, Centlivre M, Harwig A, Ooms M, Page M, Almond N, Yuan F, Piatak M, Lifson JD, Berkhout B (2008). Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution. *Retrovirology* 5: 44.
59. Berry N, Stebbings R, Ferguson D, Ham C, Alden J, Brown S, Jenkins A, Lines J, Duffy L, Davis L, Elsley W, Page M, Hull R, Stott J, Almond N (2008) Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmac8) *J Gen Virol* 89: 2240-51.
60. Kleibeuker W, Zhou X, Centlivre M, Legrand N, Page M, Almond N, Berkhout B, Das AT (2009). A sensitive cell-based assay to measure the doxycycline concentration in biological samples. *Hum Gene Ther.* 20: 524-30.
61. Mee ET, Berry N, Ham C, Aubertin A, Lines J, Hall J, Stebbings R, Page M, Almond N, Rose NJ (2010). Mhc haplotype M3 is associated with early control of SHIVsbg infection in Mauritian cynomolgus macaques. *Tissue antigens* April 14 epub.
62. Berry, N. *et al.* Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques. *PLoS One* 6, e23092 (2011).
63. Cranage, M. P. *et al.* Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. *Vaccine* 29, 1421–30 (2011).
64. Li, B. *et al.* Vaccination with live attenuated simian immunodeficiency virus causes dynamic changes in intestinal CD4+CCR5+ T cells. *Retrovirology* 8, 8 (2011).
65. Page, M. *et al.* Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model. *Retrovirology* 9, 56 (2012).
66. Stebbings, R. *et al.* Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine. *PLoS One* 7, e50397 (2012).
67. Hassall, M. *et al.* The production, characterisation and application of monoclonal antibodies generated by immunisation with HIV-1C clade RGP140 envelope protein. *J. Virol. Methods* 194, 89–93 (2013).
68. Manoussaka, M. S. *et al.* Conditionally-live attenuated SIV upregulates global T effector memory cell frequency under replication permissive conditions. *Retrovirology* 10, 59 (2013).



69. Stebbings, R. *et al.* Immunogenicity of a recombinant measles HIV-1 subtype C vaccine. *Vaccine* **31**, 6079–86 (2013).
70. Bissett, S. L. *et al.* Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins. *Vaccine* (2014). doi:10.1016/j.vaccine.2014.07.116
71. Ferguson, D. *et al.* Early Biodistribution and Persistence of a Protective Live Attenuated SIV Vaccine Elicits Localised Innate Responses in Multiple Lymphoid Tissues. *PLoS One* **9**, e104390 (2014).
72. Page, M. *et al.* Complement-mediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to siv challenge in the macaque model for HIV/AIDS. *PLoS One* **9**, e88735 (2014).